Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I

NCT06926621 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT06926621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
April 28, 2025
Completion date
January 30, 2029
Enrollment
44 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

myotonic dystrophy type 1 (dm1)